Logo image of IRMD

IRADIMED CORP (IRMD) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:IRMD - US46266A1097 - Common Stock

100.86 USD
-3.03 (-2.92%)
Last: 1/23/2026, 8:06:08 PM
100.86 USD
0 (0%)
After Hours: 1/23/2026, 8:06:08 PM
Fundamental Rating

7

IRMD gets a fundamental rating of 7 out of 10. The analysis compared the fundamentals against 186 industry peers in the Health Care Equipment & Supplies industry. IRMD gets an excellent profitability rating and is at the same time showing great financial health properties. IRMD has a decent growth rate and is not valued too expensively. These ratings could make IRMD a good candidate for quality investing.


Dividend Valuation Growth Profitability Health

9

1. Profitability

1.1 Basic Checks

  • In the past year IRMD was profitable.
  • In the past year IRMD had a positive cash flow from operations.
  • IRMD had positive earnings in each of the past 5 years.
  • Each year in the past 5 years IRMD had a positive operating cash flow.
IRMD Yearly Net Income VS EBIT VS OCF VS FCFIRMD Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5M 10M 15M 20M 25M

1.2 Ratios

  • IRMD's Return On Assets of 18.47% is amongst the best of the industry. IRMD outperforms 98.92% of its industry peers.
  • IRMD has a better Return On Equity (21.54%) than 94.62% of its industry peers.
  • Looking at the Return On Invested Capital, with a value of 19.30%, IRMD belongs to the top of the industry, outperforming 97.31% of the companies in the same industry.
  • Measured over the past 3 years, the Average Return On Invested Capital for IRMD is significantly above the industry average of 8.84%.
  • The 3 year average ROIC (18.78%) for IRMD is below the current ROIC(19.30%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA 18.47%
ROE 21.54%
ROIC 19.3%
ROA(3y)17.74%
ROA(5y)13.28%
ROE(3y)21.21%
ROE(5y)15.76%
ROIC(3y)18.78%
ROIC(5y)N/A
IRMD Yearly ROA, ROE, ROICIRMD Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5 10 15 20 25

1.3 Margins

  • IRMD has a better Profit Margin (26.31%) than 95.70% of its industry peers.
  • In the last couple of years the Profit Margin of IRMD has remained more or less at the same level.
  • IRMD has a better Operating Margin (30.87%) than 98.39% of its industry peers.
  • In the last couple of years the Operating Margin of IRMD has grown nicely.
  • Looking at the Gross Margin, with a value of 77.07%, IRMD belongs to the top of the industry, outperforming 89.25% of the companies in the same industry.
  • IRMD's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 30.87%
PM (TTM) 26.31%
GM 77.07%
OM growth 3Y8.49%
OM growth 5Y5.96%
PM growth 3Y5.58%
PM growth 5Y0.99%
GM growth 3Y0.12%
GM growth 5Y-0.04%
IRMD Yearly Profit, Operating, Gross MarginsIRMD Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 40 60 80

9

2. Health

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), IRMD is creating value.
  • IRMD has more shares outstanding than it did 1 year ago.
  • Compared to 5 years ago, IRMD has more shares outstanding
  • There is no outstanding debt for IRMD. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
IRMD Yearly Shares OutstandingIRMD Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M
IRMD Yearly Total Debt VS Total AssetsIRMD Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

2.2 Solvency

  • An Altman-Z score of 51.42 indicates that IRMD is not in any danger for bankruptcy at the moment.
  • Looking at the Altman-Z score, with a value of 51.42, IRMD belongs to the top of the industry, outperforming 98.92% of the companies in the same industry.
  • IRMD has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z 51.42
ROIC/WACC1.93
WACC10%
IRMD Yearly LT Debt VS Equity VS FCFIRMD Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

2.3 Liquidity

  • A Current Ratio of 6.64 indicates that IRMD has no problem at all paying its short term obligations.
  • IRMD has a better Current ratio (6.64) than 84.95% of its industry peers.
  • A Quick Ratio of 5.72 indicates that IRMD has no problem at all paying its short term obligations.
  • The Quick ratio of IRMD (5.72) is better than 85.48% of its industry peers.
Industry RankSector Rank
Current Ratio 6.64
Quick Ratio 5.72
IRMD Yearly Current Assets VS Current LiabilitesIRMD Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

6

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an nice 13.75% over the past year.
  • IRMD shows quite a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 13.92% yearly.
  • The Revenue has grown by 12.91% in the past year. This is quite good.
  • The Revenue has been growing by 13.71% on average over the past years. This is quite good.
EPS 1Y (TTM)13.75%
EPS 3Y25.74%
EPS 5Y13.92%
EPS Q2Q%9.3%
Revenue 1Y (TTM)12.91%
Revenue growth 3Y20.55%
Revenue growth 5Y13.71%
Sales Q2Q%15.69%

3.2 Future

  • Based on estimates for the next years, IRMD will show a quite strong growth in Earnings Per Share. The EPS will grow by 9.26% on average per year.
  • Based on estimates for the next years, IRMD will show a quite strong growth in Revenue. The Revenue will grow by 8.97% on average per year.
EPS Next Y15.29%
EPS Next 2Y14.48%
EPS Next 3Y9.26%
EPS Next 5YN/A
Revenue Next Year13.26%
Revenue Next 2Y11.69%
Revenue Next 3Y8.97%
Revenue Next 5YN/A

3.3 Evolution

  • The EPS growth rate is decreasing: in the next years the growth will be less than in the last years.
  • The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
IRMD Yearly Revenue VS EstimatesIRMD Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 20M 40M 60M 80M
IRMD Yearly EPS VS EstimatesIRMD Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 0.5 1 1.5 2

4

4. Valuation

4.1 Price/Earnings Ratio

  • Based on the Price/Earnings ratio of 55.42, the valuation of IRMD can be described as expensive.
  • IRMD's Price/Earnings ratio is a bit cheaper when compared to the industry. IRMD is cheaper than 68.28% of the companies in the same industry.
  • IRMD is valuated expensively when we compare the Price/Earnings ratio to 27.21, which is the current average of the S&P500 Index.
  • IRMD is valuated quite expensively with a Price/Forward Earnings ratio of 46.64.
  • Compared to the rest of the industry, the Price/Forward Earnings ratio of IRMD indicates a somewhat cheap valuation: IRMD is cheaper than 68.82% of the companies listed in the same industry.
  • The average S&P500 Price/Forward Earnings ratio is at 24.26. IRMD is valued rather expensively when compared to this.
Industry RankSector Rank
PE 55.42
Fwd PE 46.64
IRMD Price Earnings VS Forward Price EarningsIRMD Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30 40 50

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, IRMD is valued a bit cheaper than the industry average as 66.67% of the companies are valued more expensively.
  • 69.89% of the companies in the same industry are more expensive than IRMD, based on the Price/Free Cash Flow ratio.
Industry RankSector Rank
P/FCF 91.97
EV/EBITDA 48.97
IRMD Per share dataIRMD EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 2 4 6

4.3 Compensation for Growth

  • The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates IRMD does not grow enough to justify the current Price/Earnings ratio.
  • The excellent profitability rating of IRMD may justify a higher PE ratio.
PEG (NY)3.62
PEG (5Y)3.98
EPS Next 2Y14.48%
EPS Next 3Y9.26%

3

5. Dividend

5.1 Amount

  • IRMD has a yearly dividend return of 0.65%, which is pretty low.
  • Compared to an average industry Dividend Yield of 0.19, IRMD pays a better dividend. On top of this IRMD pays more dividend than 91.40% of the companies listed in the same industry.
  • With a Dividend Yield of 0.65, IRMD pays less dividend than the S&P500 average, which is at 1.82.
Industry RankSector Rank
Dividend Yield 0.65%

5.2 History

  • IRMD has paid a dividend for less than 5 years, so there is no long track record yet.
Dividend Growth(5Y)N/A
Div Incr Years0
Div Non Decr Years0
IRMD Yearly Dividends per shareIRMD Yearly Dividends per shareYearly Dividends per share 2022 2023 2024 2025 0.5 1 1.5

5.3 Sustainability

  • 39.59% of the earnings are spent on dividend by IRMD. This is a low number and sustainable payout ratio.
DP39.59%
EPS Next 2Y14.48%
EPS Next 3Y9.26%
IRMD Yearly Income VS Free CF VS DividendIRMD Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M
IRMD Dividend Payout.IRMD Dividend Payout, showing the Payout Ratio.IRMD Dividend Payout.PayoutRetained Earnings

IRADIMED CORP / IRMD FAQ

Can you provide the ChartMill fundamental rating for IRADIMED CORP?

ChartMill assigns a fundamental rating of 7 / 10 to IRMD.


Can you provide the valuation status for IRADIMED CORP?

ChartMill assigns a valuation rating of 4 / 10 to IRADIMED CORP (IRMD). This can be considered as Fairly Valued.


Can you provide the profitability details for IRADIMED CORP?

IRADIMED CORP (IRMD) has a profitability rating of 9 / 10.


What are the PE and PB ratios of IRADIMED CORP (IRMD) stock?

The Price/Earnings (PE) ratio for IRADIMED CORP (IRMD) is 55.42 and the Price/Book (PB) ratio is 13.04.


Can you provide the financial health for IRMD stock?

The financial health rating of IRADIMED CORP (IRMD) is 9 / 10.